'On consolidated basis
Quarter ended December 2025 compared with Quarter ended December 2024.
Net sales (including other operating income) of Ajanta Pharma has increased 19.95% to Rs 1374.84 crore. Operating profit margin has declined from 27.99% to 27.80%, leading to 19.14% rise in operating profit to Rs 382.24 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 17.85% to 17.07%. Purchase of finished goods cost fell from 6.67% to 3.89%. Employee cost increased from 22.53% to 24.00%. Other expenses rose from 25.69% to 27.29%.
Other income fell 17.97% to Rs 24.97 crore. PBIDT rose 15.93% to Rs 407.21 crore. Provision for interest fell 35.52% to Rs 5.1 crore.
PBDT rose 17.11% to Rs 402.11 crore. Provision for depreciation rose 20.96% to Rs 43.51 crore.
Profit before tax grew 16.66%...
Pleaselogin & subscribe to view the full report.
More Reports
|
|